慢性阻塞性肺疾病患者吸入长效支气管舒张剂与心血管风险的关联:巢式病例对照研究
该巢式病例对照研究基于台湾全民健康保险研究数据库2007至2011年数据,纳入284220例至少40岁、未使用过长效β2受体激动剂(LABA)或长效抗胆碱能药(LAMA)的COPD患者。平均随访2.0年期间,识别出37719例因冠心病、心力衰竭、缺血性卒中或心律失常就诊急诊或住院的病例,并按1:4匹配146139例对照。新启用LABA和LAMA后30天内心血管风险分别增加1.50倍(95%CI 1.35-1.67)和1.52倍(95%CI 1.28-1.80),而既往已使用者风险未见升高甚至降低;各具体药物、剂型及合并COPD方案间风险无差异。结论提示新启用LABA或LAMA与严重心血管风险增加相关,不受既往心血管病史或急性加重史影响。
要点
- COPD患者新启用LABA后30天内严重心血管事件风险增加1.50倍(95%CI 1.35-1.67;P<.001)。
- COPD患者新启用LAMA后30天内严重心血管事件风险增加1.52倍(95%CI 1.28-1.80;P<.001)。
- 既往已使用LABA或LAMA者心血管风险未见升高甚至降低。
- 各具体LABA药物、LAMA剂型及合并COPD方案间心血管风险无差异。
- 无心血管病史或无既往急性加重史亚组中新启用LABA或LAMA的心血管风险持续存在。
适用人群与场景
- 至少40岁、未使用过LABA或LAMA的COPD患者,来自台湾全民健康保险研究数据库2007至2011年理赔数据。
- 平均年龄71.4岁,男性占68.9%。
- 心血管病例平均年龄75.6岁,男性占71.6%;对照平均年龄75.2岁,男性占70.1%。
研究设计与关键结果
- 研究类型为巢式病例对照研究,纳入284220例LABA-LAMA初治COPD患者,平均随访2.0年。
- 识别37719例因冠心病、心力衰竭、缺血性卒中或心律失常就诊急诊或住院的心血管病例,按1:4匹配146139例对照。
- 新启用LABA后30天内心血管风险增加1.50倍(95%CI 1.35-1.67;P<.001)。
- 新启用LAMA后30天内心血管风险增加1.52倍(95%CI 1.28-1.80;P<.001)。
- 既往已使用LABA或LAMA者心血管风险未见升高甚至降低。
- 各具体LABA药物、LAMA剂型及合并COPD方案间心血管风险无差异。
- 替代病例交叉研究显示风险持续存在,无心血管病史或无既往急性加重史亚组中风险同样持续。
证据类型、等级与局限
- 证据类型:巢式病例对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- COPD患者新启用LABA或LAMA后30天内应关注严重心血管事件风险,尤其急诊或住院就诊时。
- 新启用LABA或LAMA的心血管风险在无心血管病史或无既往急性加重史患者中同样持续存在。
- 既往已使用LABA或LAMA者的心血管风险未见升高甚至降低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The associations between cardiovascular disease (CVD) and inhaled long-acting β2-agonists (LABAs) or long-acting antimuscarinic antagonists (LAMAs) in chronic obstructive pulmonary disease (COPD) are greatly debated. Pivotal and relevant randomized clinical trials included prior LABA or LAMA users and excluded patients with baseline CVD; therefore, cardiovascular events arising from first-time LABA or LAMA use, if any, could not be observed. There is an urgent need to examine whether new use of and duration since initiating LABAs and LAMAs could act as important determinants of cardiovascular events.
OBJECTIVE: To investigate risk of CVD associated with LABAs and LAMAs, focusing on the initiation and duration of LABA and LAMA therapies.
DESIGN, SETTING, AND PARTICIPANTS: This nested case-control study included 284 220 LABA-LAMA-naïve patients with COPD at least 40 years old (mean age, 71.4 years; 68.9% men), retrieved from the Taiwan National Health Insurance Research Database for health care claims from 2007 to 2011.
EXPOSURE: LABA or LAMA use was measured in the year preceding the event or index date, stratified by duration since initiation of LABA or LAMA treatment, new and prevalent users, concomitant COPD medications, and individual agents.
MAIN OUTCOMES AND MEASURES: Cases with inpatient or emergency care visits for coronary artery disease, heart failure, ischemic stroke, or arrhythmia were identified and individually matched to 4 randomly selected controls. Conditional logistic regressions were performed to estimate odds ratios of CVD from LABA and LAMA treatment.
RESULTS: During a mean follow-up of 2.0 years, 37 719 patients with CVD (mean age, 75.6 years; 71.6% men) and 146 139 matched controls (mean age, 75.2 years; 70.1% men) were identified. New LABA and LAMA use in COPD was associated with a 1.50-fold (95% CI, 1.35-1.67; P < .001) and a 1.52-fold (95% CI, 1.28-1.80; P < .001) increased cardiovascular risk within 30 days of initiation, respectively, whereas the risk was absent, or even reduced with prevalent use. Individual LABA agents, LAMA dosage forms, and concomitant COPD regimens did not differ in the CVD risks. The risk persisted in an alternative case-crossover study and remained across subgroups without CVD history or prior exacerbations.
CONCLUSIONS AND RELEVANCE: New initiation of LABAs or LAMAs in patients with COPD is associated with an approximate 1.5-fold increased severe cardiovascular risk, irrespective of prior CVD status and history of exacerbations.
参考来源
- Wang MT, Liou JT, Lin CW, et al. Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study. JAMA Intern Med. 2018. PMID: 29297057. doi:10.1001/jamainternmed.2017.7720
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。